Web references (as supplied by the authors)


Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. *Jama* 2010;303(13):1266-73.


Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of
1986;314(20):1269-76.

w32 Giannini EH, Brewer EJ, Jr., Kuzmina N, Shaikov A, Wallin B. Auranofin in the
treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind,
placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group.

w33 Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid
arthritis. Correlation with conventional inflammation parameters and clinical subtypes.

w34 Frosh M, Roth J. New insights in systemic juvenile idiopathic arthritis--from

treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic

w36 Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. *Expert
Opin Pharmacother* 2009;10:3049-60.

w37 Lehman TJ. Are withdrawal trials in paediatric rheumatic disease helpful? *Lancet*

treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary

efficacy and safety of infiximab plus methotrexate for the treatment of polyarticular-
course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

w40 Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and
safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a
randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet*
2008;371(9617):998-1006.

w41 Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of
continuous etanercept therapy in patients with juvenile rheumatoid arthritis. *Arthritis
Rheum 2008;58:1496-504.

w42 Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of
etanercept and methotrexate compared to treatment with etanercept only in patients with
juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. *Ann

w43 Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for

w44 Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and
safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. *Ann


Killeen OG, Gardner-Medwin JM. In juvenile idiopathic arthritis, is folate supplementation effective against methotrexate toxicity at the expense of methotrexate’s efficacy? *Arch Dis Child* 2006;91(6):537-8.


w66 Killeen OG, Gardner-Medwin JM. In juvenile idiopathic arthritis, is folate supplementation effective against methotrexate toxicity at the expense of methotrexate’s efficacy? Arch Dis Child 2006;91(6):537-8.


w71 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis ClinicalTrials.gov identifier: NCT00443430

w72 Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE-JIA) ClinicalTrials.gov identifier: NCT01015547

w73 BeSt for kids: comparing treatment strategies in juvenile idiopathic arthritis. Netherlands Trial register number: NTR1574